Clinical study on recombinant human interferon α-2b combined with adefovir dipivoxil in the treatmnet of chronic hepatitis B

VernacularTitle:重组人干扰素α-2b联合阿德福韦酯治疗慢性乙型肝炎临床研究
Author: Yan ZHOU
Publication Type:Journal Article
Keywords: Interferon; Adefovir dipivoil; Hepatitis B Chronic
From: Chinese Journal of Primary Medicine and Pharmacy 2013;20(9):1302-1303
CountryChina
Language:Chinese
Abstract: Objective To explore the short-term efficacy and side effects of recombinant human interferon α-2b (rhIFNα-2b) combined with adefovir dipivoxil in the treatment of chronic hepatitis B (HBeAg +).Methods 174 patients with chronic hepatitis B were randomly divided into three groups.60 patients in group A were given rhIFNα-2b and adefovir dipivoil.57 patients in group B were only given rhIFNα-2b.57 patients in group C were only given adefovir dipivoil.After treatment for 48 weeks,the changes of liver function and HBVM were observed in three groups.Results ALT was significantly decreased in three groups.But group A was obviously higher than group B and group C(P ＜ 0.05).The negative rate of HbeAg was 48.3％,36.8％ and 33.3％.The negative rate of HBV-DNA was 63.3％,42.1％ and 40.4％.The effect of group A was better than that of group B and group C(P ＜0.05).Side effects had not been found.Conclusion rhIFNα-2b combined with adefovir dipivoil can improve liver function and inhibit HBV.